Comparison of acamprosate and placebo in long-term treatment of alcohol dependence.
Background About 50% of alcoholic patients relapse within 3 months of treatment.
Previous studies have suggested that acamprosate may help to prevent such relapse.
The aim of our study was to assess the efficacy and safety of long-term acamprosate treatment in alcohol dependence.
Methods In this multicentre, double-blind, placebo-controlled study, we recruited 455 patients, aged 18-65 years, with chronic or episodic alcohol dependence.
Patients were randomly allocated treatment with acamprosate (1998 mg daily for bodyweight>60 kg ; 1332 mg daily for ¾60 kg) or placebo for 360 days.
Patients were assessed on the day treatment started and on days 30,90,180,270, and 360 by interview, self-report, questionnaire, and laboratory screening.
Patients were classified as abstinent, relapsing, or non-attending.
Time to first treatment failure (relapse or non-attendance) was the primary outcome measure.
Findings Seven patients were excluded from the intention-to-treat analysis because they did not attend on the first treatment day and therefore received no medication.
The acamprosate (n=224) and placebo (n=224) groups were well matched in terms of baseline demographic and alcohol-related variables. 94 acamprosate-treated and 85 placebo-treated patients completed the treatment phase : of those withdrawn, 104 (52 in each group) relapsed, 69 (33 vs 36, respectively) were lost to follow-up, 63 (31 vs 32) refused to continue treatment, 16 (15 vs 11) had concurrent illness,...
Mots-clés Pascal : Alcoolisme, Dépendance, Acamprosate, Chimiothérapie, Voie orale, Coût, Essai thérapeutique contrôlé, Traitement, Pronostic, Efficacité traitement, Adulte, Homme, Long terme, Vienne, Poitou Charente, France, Europe, Psychopathologie
Mots-clés Pascal anglais : Alcoholism, Dependence, Chemotherapy, Oral administration, Costs, Controlled therapeutic trial, Treatment, Prognosis, Treatment efficiency, Adult, Human, Long term, Vienne, Poitou-Charente, France, Europe, Psychopathology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0271141
Code Inist : 002B02B09D. Création : 199608.